Literature DB >> 17612904

The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.

Luis Ruilope1, Sverre E Kjeldsen, Alejandro de la Sierra, Giuseppe Mancia, Piero Ruggenenti, George S Stergiou, George L Bakris, Thomas D Giles.   

Abstract

Cardiovascular and renal diseases share many of the same risk factors. In fact, renal failure is usually accompanied by an increased global cardiovascular risk. Thus, preservation of kidney function might simultaneously protect the heart and the brain and, conversely, addressing cardiovascular risk factors might safeguard the kidney. This review considers the evidence supporting this approach, focusing on the protective effect of blood-pressure lowering and the ancillary actions of antihypertensive agents on renal protection. We review recent evidence on renal protection in individuals with and without diabetes, and the importance of offering a high standard of care also to those with the metabolic syndrome or prediabetes in order to prevent initial forms of renal, and as a consequence, cardiovascular damage. Intervention may be appropriate even in individuals with high-normal blood pressure, if they already have early renal and/or cardiovascular risk markers. As a consequence of these insights, thresholds for starting antihypertensive therapy are gradually falling, whereas awareness of the need for an early intervention in patients at high risk of developing renal damage and simultaneously cardiovascular disease is growing.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17612904     DOI: 10.1080/08037050701338985

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  7 in total

1.  The Framingham risk score is valuable in Europeans.

Authors:  Luis M Ruilope
Journal:  Nat Rev Nephrol       Date:  2010-01       Impact factor: 28.314

Review 2.  Renal dopaminergic system: Pathophysiological implications and clinical perspectives.

Authors:  Marcelo Roberto Choi; Nicolás Martín Kouyoumdzian; Natalia Lucía Rukavina Mikusic; María Cecilia Kravetz; María Inés Rosón; Martín Rodríguez Fermepin; Belisario Enrique Fernández
Journal:  World J Nephrol       Date:  2015-05-06

Review 3.  Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus.

Authors:  George L Bakris
Journal:  Mayo Clin Proc       Date:  2011-05       Impact factor: 7.616

Review 4.  Reactive oxygen species and dopamine receptor function in essential hypertension.

Authors:  Chunyu Zeng; Van Anthony M Villar; Peiying Yu; Lin Zhou; Pedro A Jose
Journal:  Clin Exp Hypertens       Date:  2009-04       Impact factor: 1.749

Review 5.  Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?

Authors:  Luis Ruilope; Joseph Izzo; Hermann Haller; Bernard Waeber; Suzanne Oparil; Michael Weber; George Bakris; James Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-06       Impact factor: 3.738

6.  Cardiovascular and Renal Links along the Cardiorenal Continuum.

Authors:  José A García-Donaire; Luis M Ruilope
Journal:  Int J Nephrol       Date:  2011-03-31

7.  ASH position paper: treatment of hypertension in patients with diabetes-an update.

Authors:  George L Bakris; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-09       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.